Tuis600664 • SHA
add
Harbin Pharmaceutical Group Co., Ltd.
Vorige sluiting
¥3,64
Jaarwisseling
¥2,41 - ¥4,13
Markkapitalisasie
9,49 mjd CNY
Gemiddelde volume
35,52 m
P/V-verhouding
16,19
Dividend-opbrengs
-
Primêre beurs
SHA
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CNY) | Jun. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 4,00 mjd | 6,05% |
Bedryfskoste | 977,13 m | 23,80% |
Netto inkomste | 166,64 m | 175,81% |
Netto winsgrens | 4,17 | 160,62% |
Wins per aandeel | — | — |
EBITDA | 274,38 m | 50,36% |
Effektiewe belastingkoers | 22,99% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CNY) | Jun. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 3,18 mjd | 22,51% |
Totale bates | 14,24 mjd | 3,68% |
Totale aanspreeklikheid | 8,48 mjd | -0,98% |
Totale ekwiteit | 5,76 mjd | — |
Uitstaande aandele | 2,52 mjd | — |
Prys om te bespreek | 1,82 | — |
Opbrengs op bates | 3,80% | — |
Opbrengs op kapitaal | 7,00% | — |
Kontantvloei
Netto kontantverandering
| (CNY) | Jun. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 166,64 m | 175,81% |
Kontant van bedrywe | 344,42 m | -1,27% |
Kontant van beleggings | -15,62 m | -70,10% |
Kontant van finansiering | 15,19 m | 115,53% |
Netto kontantverandering | 344,23 m | 40,80% |
Beskikbare kontantvloei | 377,94 m | 6,99% |
Meer oor
Harbin Pharmaceutical Group Co., Ltd. is a Chinese partially state-owned company engaged in the research & development, manufacture, and sale of pharmaceutical products. HPGC medication offerings include traditional Chinese medicine and biopharmaceuticals; its main offerings include antibiotics, including amoxicillin and penicillin, and dietary supplements, including zinc gluconate and calcium gluconate.
The company owns both Renmintongtai, a drugstore chain and medical wholesaler for the domestic market, and GNC, a U.S.-based international retailer of supplements and wellness products. Wikipedia
Gestig
1988
Webwerf
Werknemers
9 853
